Cancer Drug Parity Act of 2025

The Cancer Drug Parity Act of 2025 (HR4101) was introduced in the House on June 24, 2025, and subsequently referred to the House Committee on Education and Workforce. This bill is in the early stages of the legislative process. Its core objective is to amend the Employee Retirement Income Security Act of 1974 (ERISA) to mandate that group health plans provide cost-sharing for oral anticancer drugs on terms no less favorable than those for intravenously administered anticancer medications. This bill does not involve direct federal funding or appropriations. Instead, it operates through a regulatory mandate on private health insurance plans. The mechanism is a change to ERISA, which governs most private sector employee benefit plans. By requiring parity in cost-sharing, the bill aims to remove financial barriers for patients opting for oral anticancer treatments, which are often preferred for their convenience but can have higher out-of-pocket costs due to how they are classified by insurers compared to provider-administered drugs. Structural winners would be pharmaceutical companies that develop and market oral anticancer medications, as reduced patient costs are expected to drive increased demand and prescription volumes. Companies such as Pfizer ($PFE), Johnson & Johnson ($JNJ), Merck ($MRK), Bristol Myers Squibb ($BMY), Amgen ($AMGN), Eli Lilly ($LLY), and Gilead Sciences ($GILD) have significant oral oncology portfolios and would likely see a positive impact on their sales. Conversely, health insurance providers offering group health plans would be the obligated parties, potentially facing increased costs or adjustments to their benefit structures to comply with the parity requirement. The bill is currently in committee, indicating that it has a long legislative path ahead, including potential committee hearings, markups, and votes in both the House and Senate before it could be considered for presidential signature. There is no related presidential action that directly amplifies or conflicts with this specific bill's objective; the Executive Order on Accelerating Medical Treatments for Serious Mental Illness focuses on psychedelic-based therapies for mental health, a distinct area from cancer drug cost-sharing.